Biotech
Aug. 11, 2011
William Gaede
Gaede spends time helping his clients fathom "the real world implications" of intellectual property issues.
"The law has been very active in the patent space over the past three to four years," he said. "That has changed the landscape regarding investment and deal structure in life science transactions and litigation."
In general, he said, patent rights have been weakened.
"Life science companies...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In